Adverse drug reactions associated with concurrent acute psychiatric treatment and Covid-19 drug therapy

References

• AFP. 2020. Coronavirus pandemic still accelerating: WHO chief – France 24.
   Google Scholar
• Bilbul M, Paparone P, Kim AM, Mutalik S, Ernst CL. 2020. Psychopharmacology of COVID-19. Psychosomatics. 61(5):411–427.
   PubMed Web of Science ®Google Scholar
• Bishara D, Kalafatis C, Taylor D. 2020. Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. Ther Adv Psychopharmacol. 10:2045125320935306.
   Web of Science ®Google Scholar
• Boland X, Dratcu L. 2020a. COVID-19 and acute inpatient psychiatry: the shape of things to come. Int J Psych Clin Pract. Aug 5;1–3.
   PubMed Web of Science ®Google Scholar
• Boland X, Dratcu L. 2020b. ECT and COVID-19 in acute inpatient psychiatry: more than clinical issues alone. J Ect. 36(3):223–224.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, et al. 2020. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 383(6):517–525.
   PubMed Web of Science ®Google Scholar
• Campion J, Javed A, Sartorius N, Marmot M. 2020. Addressing the public mental health challenge of COVID-19. Lancet Psychiatr. 7(8):657–659.
   PubMed Web of Science ®Google Scholar
• Chatterjee SS, Malathesh BC, DAS S, Singh OP. 2020. Interactions of recommended COVID-19 drugs with commonly used psychotropics. Asian J Psychiatr. 52:102173.
   PubMed Web of Science ®Google Scholar
• Dudley K, Liu X, DE Haan S. 2017. Chlorpromazine dose for people with schizophrenia. Cochrane Database Syst Rev. 4:CD007778.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ. 2020. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc. 95(6):1213–1221.
   PubMed Web of Science ®Google Scholar
• Ilie PC, Stefanescu S, Smith L. 2020. The role of vitamin D in the prevention of Coronavirus disease 2019 infection and mortality. Aging Clin Exp Res. 32(7):1195–1198.
   PubMed Web of Science ®Google Scholar
• Iversen TSJ, Steen NE, Dieset I, Hope S, Morch R, Gardsjord ES, Jorgensen KN, Melle I, Andreassen OA, Molden E, et al. 2018. Side effect burden of antipsychotic drugs in real life – Impact of gender and polypharmacy. Prog Neuropsychopharmacol Biol Psychiatr. 82:263–271.
   PubMed Web of Science ®Google Scholar
• Javelot H, Llorca PM, Drapier D, Fakra E, Hingray C, Meyer G, Dizet S, Egron A, Straczek C, Roser M, et al. 2020. [Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. Encephale. 46(3S):S14–S34.
   PubMedGoogle Scholar
• Kumar A, Kubota Y, Chernov M, Kasuya H. 2020. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. Med Hypotheses. 144:109848.
   PubMed Web of Science ®Google Scholar
• Li L. 2020. Challenges and priorities in responding to COVID-19 in inpatient psychiatry. Psychiatr Serv. 71(6):624–626.
   PubMed Web of Science ®Google Scholar
• Li X, Wang Y, Agostinis P, Rabson A, Melino G, Carafoli E, Shi Y, Sun E. 2020. Is hydroxychloroquine beneficial for COVID-19 patients? Cell Death Dis. 11(7):512.
   PubMed Web of Science ®Google Scholar
• Monzani A, Genoni G, Scopinaro A, Pistis G, Kozel D, Secco GG. 2020. QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine. Eur J Clin Invest. 50(6):e13258.
   PubMed Web of Science ®Google Scholar
• Naksuk N, Lazar S, Peeraphatdit TB. 2020. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 9(3):215–221.
   PubMed Web of Science ®Google Scholar
• Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. 1981. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 30(2):239–245.
   PubMed Web of Science ®Google Scholar
• Niddkd NIODADAKD. 2012. Adverse drug reaction probability scale (Naranjo) in drug induced liver injury. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive.
   Google Scholar
• Nielsen J, Meyer JM. 2012. Risk factors for ileus in patients with schizophrenia. Schizophr Bull. 38(3):592–598.
   PubMed Web of Science ®Google Scholar
• Roden DM, Harrington RA, Poppas A, Russo AM. 2020. Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment. J Am Coll Cardiol. 75(20):2623–2624.
   PubMed Web of Science ®Google Scholar
• Sienaert P, Lambrichts S, Popleu L, VAN Gerven E, Buggenhout S, Bouckaert F. 2020. Electroconvulsive therapy during COVID-19-times: our patients cannot wait. Am J Geriatr Psychiatr. 28(7):772–775.
   PubMed Web of Science ®Google Scholar
• Siskind D, Honer WG, Clark S, Correll CU, Hasan A, Howes O, Kane JM, Kelly DL, Laitman R, Lee J, et al. 2020. Consensus statement on the use of clozapine during the COVID-19 pandemic. J Psychiatr Neurosci. 45(4):200061.
   PubMedGoogle Scholar
• Smith S. 2010. Gender differences in antipsychotic prescribing. Int Rev Psychiatr. 22(5):472–484.
   PubMed Web of Science ®Google Scholar
• Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, Jiang B. 2020. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet. 395(10228):e52.
   PubMed Web of Science ®Google Scholar
• Wu R, Wang L, Kuo HD, Shannar A, Peter R, Chou PJ, Li S, Hudlikar R, Liu X, Liu Z, Poiani GJ, Amorosa L, Brunetti L, et al. 2020. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. May 11;1–15.
   PubMedGoogle Scholar
• Yao H, Chen JH, Xu YF. 2020. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 7(4):e21.
   PubMed Web of Science ®Google Scholar